These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 1646613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
    Adamus WS, Heuer H, Meade CJ.
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 8. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 9. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

  • 10. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 11. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
    Akagi M, Nishioka E, Kanoh R, Tachibana M, Fukuishi N.
    Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
    [Abstract] [Full Text] [Related]

  • 12. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
    Yue TL, Gleason MM, Gu JL, Lysko PG, Hallenbeck J, Feuerstein G.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
    [Abstract] [Full Text] [Related]

  • 13. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 14. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A, Tahraoui L, Sedivy P, Cavero I.
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [Abstract] [Full Text] [Related]

  • 15. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L, Floch A, Cavero I.
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
    [Abstract] [Full Text] [Related]

  • 16. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies.
    Castro-Faria-Neto HC, Araújo CV, Moreira S, Bozza PT, Thomas G, Barbosa-Filho JM, Cordeiro RS, Tibiriçá EV.
    Planta Med; 1995 Apr; 61(2):106-12. PubMed ID: 7753914
    [Abstract] [Full Text] [Related]

  • 17. Eosinophil chemotaxis induced by several biologically active substances and the effects of apafant on it in vitro.
    Nabe T, Yamamura H, Kohno S.
    Arzneimittelforschung; 1997 Oct; 47(10):1112-6. PubMed ID: 9368704
    [Abstract] [Full Text] [Related]

  • 18. [Characterization of platelet-activating factor (PAF)-receptors in neutrophilic and eosinophilic granulocytes].
    Ukena D, Dent G, Chanez P, Barnes PJ, Sybrecht GW.
    Pneumologie; 1990 Feb; 44 Suppl 1():531-2. PubMed ID: 2164200
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S, Ortega MP, Priego JG, de Casa-Juana MF, Sunkel C, Sánchez Crespo M.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [Abstract] [Full Text] [Related]

  • 20. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP, García MC, Gijón MA, de Casa-Juana MF, Priego JG, Sanchez Crespo M, Sunkel C.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.